Rafael (NYSE:RFL – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, FiscalAI reports. Rafael had a negative net margin of 3,321.74% and a negative return on equity of 41.27%. The firm had revenue of $0.24 million during the quarter.
Rafael Stock Down 6.5%
NYSE RFL traded down $0.08 during trading hours on Thursday, reaching $1.13. 139,160 shares of the company were exchanged, compared to its average volume of 134,958. The stock has a market capitalization of $58.81 million, a P/E ratio of -1.66 and a beta of 0.35. Rafael has a 1 year low of $1.08 and a 1 year high of $3.96. The business’s 50 day simple moving average is $1.87 and its 200-day simple moving average is $1.69.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Rafael stock. Kahn Brothers Group Inc. purchased a new position in shares of Rafael Holdings, Inc. (NYSE:RFL – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 58,557 shares of the company’s stock, valued at approximately $73,196,000. Rafael comprises 0.1% of Kahn Brothers Group Inc.’s investment portfolio, making the stock its 13th largest holding. Kahn Brothers Group Inc. owned 0.11% of Rafael at the end of the most recent quarter. 11.30% of the stock is owned by institutional investors.
Analysts Set New Price Targets
RFL has been the topic of a number of research analyst reports. Wall Street Zen upgraded Rafael to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rafael in a research report on Tuesday, August 25th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Check Out Our Latest Stock Report on Rafael
About Rafael
Rafael Holdings, Inc (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.
Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613).
See Also
- Five stocks we like better than Rafael
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
